Adalta Capital Management LLC Makes New $192,000 Investment in Kenvue Inc. $KVUE

Adalta Capital Management LLC bought a new position in Kenvue Inc. (NYSE:KVUE) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 8,000 shares of the company’s stock, valued at approximately $192,000.

Other large investors have also added to or reduced their stakes in the company. Pittenger & Anderson Inc. bought a new stake in Kenvue in the 1st quarter worth approximately $30,000. TruNorth Capital Management LLC purchased a new position in shares of Kenvue during the 1st quarter worth $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue during the 1st quarter worth $37,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after acquiring an additional 1,287 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Kenvue by 120.6% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock worth $41,000 after acquiring an additional 929 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their price target on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, July 25th. UBS Group dropped their price target on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, July 17th. Royal Bank Of Canada dropped their price target on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Citigroup lowered their target price on shares of Kenvue from $24.50 to $22.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 15th. Finally, Barclays lowered their target price on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus price target of $24.38.

Kenvue Stock Down 9.3%

KVUE opened at $18.64 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $25.17. The firm’s fifty day moving average is $21.37 and its 200 day moving average is $22.38. The stock has a market cap of $35.76 billion, a price-to-earnings ratio of 25.18, a price-to-earnings-growth ratio of 2.67 and a beta of 0.83.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. Kenvue’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.5%. The ex-dividend date was Wednesday, August 13th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is presently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.